HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Equity Research
Zacks Rank can tell you which stocks to buy and sell. Zacks Equity Research tells you why. Click here to learn more.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


NVS: Novartis Ag - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

NOVARTIS AG (NYSE)
NVS 53.58 0.50 (0.94%) Vol.  2,507,700 16:01 ET

Day Low - High 53.06 - 53.79
52wk Low - High 33.34 - 56.42
Avg Volume 2,906,479
Industry LARGE CAP PHARMA
Market Cap 120.56 B
Div - Yield 1.45 - 2.74
PE (forward) 11.59
PEG Ratio 2.67
Current Year Est. 4.58
EPS Last Year 3.69
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


downgraded 01/14/2010
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 01/26/2010
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
NOVARTIS AG NVS PREMIUM
ALCON INC ACL PREMIUM
ABBOTT LABS ABT PREMIUM
ALLERGAN INC AGN PREMIUM
See all LARGE CAP PHARMA Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.70
ABR (Last Week) 1.70
# of Recs in ABR 10
Average Target Price 60.37
Industry Rank by ABR 136 out of 217
Rank in Industry 4 out of 15
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate NVS?
Buy
Sell
Find out what the Zacks Community
thinks of NVS at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR NVS
Zacks Blog: Positive Results on Amgen Drug
Feb 09, 2010
Zacks Blog: Expansion for Glaxo's Tykerb
Feb 01, 2010
Zacks Equity Research: Report for NVS
Jan 26, 2010
Zacks Blog: Novartis’ MS Therapy Advances
Jan 22, 2010
Zacks Blog: Novartis Offer Inadequate for Alcon
Jan 21, 2010
Zacks Blog: Another Deal for Novartis
Jan 20, 2010
Zacks Blog: HGSI to Seek Drug Approval in 2Q
Jan 14, 2010
Zacks Blog: Alnylam Pharma Guides
Jan 14, 2010
More Zacks Commentary
NEWS
Drug Approvals: AZN, AMGN, NVS
Feb 09, 2010
Novartis AG (NVS) In Tight Support/Resistance Range
Feb 09, 2010
Debiopharm Group signs licensing agreement with Novartis for Debio 025 for hepatitis C
Feb 09, 2010
Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
Feb 09, 2010
Lupin Receives FDA Approval for Amlodipine/Benazepril Capsules
Feb 08, 2010
SciClone and Sigma-Tau Announce Additional Positive Results inClinical Study Examining ZADAXIN's Ability to Enhance Response toH1N1 Vaccine
Feb 08, 2010
Research and Markets: Partnering Agreements with Novartis 2010
Feb 05, 2010
Research and Markets: Partnering Agreements with Novartis 2010
Feb 05, 2010
More News
EARNINGS ESTIMATES
  This Quarter
03/2010
Next Quarter
06/2010
This Year
12/2010
Next Year
12/2011
Average Estimate 1.25 1.19 4.58 4.96
Number of Estimates 2 2 7 4
Low Estimates 1.05 1.13 3.78 4.26
High Estimate 1.46 1.25 5.23 5.45
Year Ago EPS 0.87 0.89 3.70 4.58
EPS Growth 44.25% 33.71% 23.75% 8.22%

More Estimates

COMPANY DESCRIPTION
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.

Full Company Report
FINANCIALS
EPS TTM 3.69
Sales 44267
Net Income 8445
Price/Earnings 14.38
Price/Book 2.1
Price/Cash Flow 14.26
Price/Sales 2.71


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research